Results 201 to 210 of about 128,993 (222)
Some of the next articles are maybe not open access.
P & T : a peer-reviewed journal for formulary management, 2014
Unlike a generic drug, a "generic" biologic won't be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the "biosimilars" that will soon appear on the market.
openaire +1 more source
Unlike a generic drug, a "generic" biologic won't be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the "biosimilars" that will soon appear on the market.
openaire +1 more source
Biosimilar Monoclonal Antibodies in China: A Patent Review
Bioengineered, 2022Ji-Fu Wei, Nan Wu
exaly
Economics as a guide to developing public policies for biosimilar pharmaceutical products
Queen Mary Journal of Intellectual Property, 2012openaire +1 more source
Clinical Safety of Biosimilar Recombinant Human Erythropoietins
Expert Opinion on Drug Safety, 2012Karen M MacDonald, Ivo Abraham
exaly
Clinical Safety of Biosimilar Recombinant Human Granulocyte Colony-Stimulating Factors
Expert Opinion on Drug Safety, 2013Karen M MacDonald, Ivo Abraham
exaly
Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose?
Diabetes Care, 2015Philip D Home
exaly

